RxDoctor Payments Data

Katrina Vankouwenberg, PA

Physician Assistant · Cheektowaga, NYNPI 1275027112

Payments from drug & device makers

$1,127in general payments, 2019–2025

Across 96 payments — averaging $11.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$404
  • Sumitomo Pharma America, Inc.$277
  • 180 Medical, Inc.$165
  • Urovant Sciences Inc$145
  • AbbVie$50
  • Novo Nordisk$24
  • plus $64 from 4 others

What the payments were for

  • Food & beverage$96385%
  • Education$16515%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,127 in reported general payments places this provider in the 75th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$6,625
Medicare patients
70
Services billed
121

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron199$154,606
GemtesaVibegron177$141,337
Trospium Chloride ErTrospium Chloride53$10,649
Mirabegron ErMirabegron13$10,368
Tamsulosin Hcl451$7,612
Cefpodoxime Proxetil121$5,508
Trospium Chloride119$5,389
Solifenacin Succinate132$4,372
Silodosin52$4,086
Estradiol37$3,100
Alfuzosin Hcl ErAlfuzosin Hcl92$2,358
Testosterone15$1,714
Tadalafil15$1,513
NitrofurantoinNitrofurantoin Macrocrystal68$1,345
Testosterone Cypionate23$1,196

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$404$154,606199 claims
Sumitomo Pharma America, Inc.Gemtesa$277$141,337177 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Cheektowaga

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →